Cash raises for Inventiva, Akeso, Capricor

With its cash pile shrinking, Inventiva S.A. (Euronext: IVA; NASDAQ:IVA) forged a tranched deal with an investor syndicate that will drive late-stage testing of lanifibranor to treat metabolic dysfunction-associated steatohepatitis.

The French biotech will immediately receive €94.1 million ($102.1 million) from a syndicate led by New Enterprise Associates, BVF Partners and Samsara BioCapital. If conditions are met in the future, the deal could supply Inventiva with a total of €348 million from the investors, plus another $30 million under a separate licensing agreement with Chia Tai Tianqing Pharmaceutical (Guangzhou) Co. Ltd...